Spinal muscular atrophy with progressive myoclonic epilepsy

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC

Spinal muscular atrophy with progressive myoclonic epilepsy
Synonyms	N/A
Pronounce	N/A
Specialty	N/A
Symptoms	Muscle weakness, myoclonus, seizures
Complications	N/A
Onset	Childhood
Duration	Chronic
Types	N/A
Causes	Mutations in the ASAH1 gene
Risks	Family history of the condition
Diagnosis	Genetic testing, Electromyography
Differential diagnosis	Spinal muscular atrophy, Epilepsy, Myoclonic epilepsy
Prevention	N/A
Treatment	Supportive care, Anticonvulsants
Medication	N/A
Prognosis	Variable, often progressive
Frequency	Rare
Deaths	N/A

A rare genetic disorder affecting the nervous system

Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) is a rare genetic disorder characterized by the combination of spinal muscular atrophy (SMA) and progressive myoclonic epilepsy (PME). This condition is caused by mutations in the ASAH1 gene, which is responsible for encoding the enzyme acid ceramidase. The disorder is inherited in an autosomal recessive pattern.

Clinical Features

SMA-PME is marked by the presence of both neuromuscular and neurological symptoms. The primary features include:

Spinal Muscular Atrophy

Individuals with SMA-PME exhibit symptoms of spinal muscular atrophy, which include:

• Progressive muscle weakness
• Muscle atrophy
• Loss of motor skills
• Difficulty with movement and coordination

These symptoms are due to the degeneration of motor neurons in the spinal cord, leading to muscle wasting and weakness.

Progressive Myoclonic Epilepsy

The epilepsy component of SMA-PME is characterized by:

• Myoclonic seizures
• Generalized tonic-clonic seizures
• Progressive worsening of seizure activity over time

Myoclonic seizures are sudden, involuntary muscle jerks that can affect various parts of the body. The epilepsy in SMA-PME is often difficult to control with standard antiepileptic drugs.

Genetics

SMA-PME is caused by mutations in the ASAH1 gene, located on chromosome 8. This gene encodes the enzyme acid ceramidase, which is involved in the metabolism of ceramides, a type of lipid molecule. Mutations in ASAH1 lead to a deficiency in acid ceramidase activity, resulting in the accumulation of ceramides and subsequent cellular dysfunction. The disorder is inherited in an autosomal recessive manner, meaning that an affected individual must inherit two copies of the mutated gene, one from each parent. Carriers, who have only one copy of the mutation, typically do not show symptoms.

Diagnosis

Diagnosis of SMA-PME involves a combination of clinical evaluation, genetic testing, and neurophysiological studies. Key diagnostic steps include:

• Clinical assessment of neuromuscular and seizure symptoms
• Genetic testing to identify mutations in the ASAH1 gene
• Electromyography (EMG) to assess muscle function
• Electroencephalography (EEG) to evaluate brain activity and seizure patterns

Management

There is currently no cure for SMA-PME, and treatment focuses on managing symptoms and improving quality of life. Management strategies include:

• Physical therapy to maintain muscle strength and mobility
• Antiepileptic medications to control seizures
• Supportive care, including respiratory support if needed

Prognosis

The prognosis for individuals with SMA-PME varies depending on the severity of symptoms and the effectiveness of seizure management. The condition is progressive, and individuals may experience significant disability over time.

See also

• Spinal muscular atrophy
• Progressive myoclonic epilepsy
• Genetic disorders
• Epilepsy